CCR Collaborative Bioinformatics Resource

CCR协作生物信息学资源（CCBR）是一个组织保护伞，为CCR研究人员提供了一种机制，以获得许多不同类型的生物信息学援助，以促进他们的研究目标。该实体汇集了NCI内许多不同的生物信息学专业知识，在广泛的生物信息学主题方面具有优势。CCBR目前正在为CCR内的80多名主要研究者提供支持，并正在开展与几个不同的一般领域相关的120个项目，包括对各种癌症基因组学领域的支持。最新的努力是在单细胞基因组学领域。导致高端出版物的合作实例包括：1）CLIC 4和miR-142- 3 p在头颈部鳞状细胞癌中的调控关系（Yuspa）; 2）首次在BCBL-1细胞中从KSHV基因组的所有拷贝中完全敲除病毒ORF 57基因（Zheng）; 3）证明转移瘤和原发性肿瘤之间甲基化的差异，证明DNMT 3B在表观遗传修饰中的作用，允许癌细胞定殖于不同组织（Yang）; 4）肝癌的转录组数据用于识别四个独特的患者群，发现其具有不同的生存结果（Wang）;和5）外显子组-seq数据的初级和次级分析，以及整合可视化，包括体细胞突变，种系祖先，和突变特征分析，以证明少数群体中癌症的健康差异（Ryan）。

The CCR Collaborative Bioinformatics Resource (CCBR) is an organizational umbrella which provides a mechanism for CCR researchers to obtain many different types of bioinformatics assistance to further their research goals. This entity pulls together many different bioinformatics expertise within NCI, with strengths in a broad range of bioinformatics topics. The CCBR currently is providing support to over 80 Principal Investigators within CCR and are working on 120 projects related to several different general areas, including support to a wide variety of cancer genomics areas. The newest efforts have been in the area of single-cell genomics. Examples of collaborations leading to high-end publications include: 1) Regulatory relationships between CLIC4 and miR-142-3p in head and neck squamous cell cancers (Yuspa); 2) The first complete knockout of viral ORF57 gene from all copies of KSHV genome in BCBL-1 cells (Zheng); 3) Demonstration of the differences in methylation between metastases and primary tumors, demonstrating the effect of DNMT3B in epigenetic modifications allowing cancer cells to colonize different tissues (Yang); 4) The transcriptomic data of liver cancer used to identify four unique patient clusters, which were found to have different survival outcomes (Wang); and 5) Primary and secondary analyses of the exome-seq data, as well as integrative visualizations, including somatic mutations, germline ancestry, and mutational signatures analyses to demonstrate health disparities in cancer among minority populations (Ryan).